Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,910.50
Bid: 1,909.50
Ask: 1,911.00
Change: 30.00 (1.60%)
Spread: 1.50 (0.079%)
Open: 1,903.00
High: 1,911.50
Low: 1,887.50
Prev. Close: 1,880.50
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

24 Jul 2014 08:43

Hikma Pharmaceuticals To Acquire Manufacturing Site From Ben Venue

Read more
23 Jul 2014 14:17

Sector movers: Weak results, outlook from Glaxo sink pharma stocks

A slump in the share price of GlaxoSmithKline dragged the pharmaceuticals and biotechnology sector into the red on Wednesday as the drugmaker disappointed with a drop in quarterly sales and its full-year outlook. The company announced at midday that it has slashed its 2014 outlook as it reported a

Read more
22 Jul 2014 11:29

BUZZ-European pharma: 7-year high P/E in focus as M&A fervour pauses

** A pause in the heady stream of M&A headlines around the European healthcare sector & earnings season shines the spotlight on 7-year high valuations. ** Deal-making and the popularity of defensives have made sector a big draw for investors this year second only to utilities. http://link.r

Read more
18 Jul 2014 10:59

UK WINNERS & LOSERS: Shire Gains As Takeover By AbbVie Confirmed

Read more
18 Jul 2014 09:08

UK BROKER RATINGS: Exane BNP Upgrades Burberry To Outperform

Read more
18 Jul 2014 07:55

Friday broker round-up UPDATE

Barclays: Credit Suisse cuts target price from 275p to 235p retaining a neutral rating. Barratt Developments: Liberum Capital reduces target price from 468p to 387p and downgrades to hold. Bellway: Liberum Capital reduces target price from 1900p to 1764p, while leaving its buy recommendation uncha

Read more
18 Jul 2014 07:25

UK MORNING BRIEFING: Shares Lower On Ukraine Crash, Gaza Offensive

Read more
17 Jul 2014 11:07

Thursday broker round-up UPDATE

Antofagasta: Canaccord Genuity cuts target price from 870p to 835p and maintains a hold recommendation. African Minerals: Canaccord Genuity reduces target price from 230p to 170p and keeps a buy recommendation. Ashmore Group: Goldman Sachs downgrades to neutral with a target price of 430p. Barcla

Read more
23 Jun 2014 13:44

DIRECTOR DEALINGS: Hikma Senior Manager Sells Shares

Read more
20 Jun 2014 13:56

Sector movers: Shire soars as M&A fever boosts pharma, health stocks

News that Shire has rejected a £27bn approach by AbbVie sent shares in the pharmaceutical and healthcare equipment sectors higher on Friday as yet more M&A continued to give sentiment a boost. "A bit of M&A excitement has been just the ticket to enliven trading on what may otherwise have been somet

Read more
29 May 2014 09:18

DIRECTOR DEALINGS: Hikma Pharmaceuticals Chairman Exercises Options

LONDON (Alliance News) - Hikma Pharmaceuticals PLC Thursday said Chairman Said Darwazah exercised options over 75,924 shares at no cost under a company share plan Thursday. Following this transaction, Darwazah has a total holding of 11 million shares, which represents 5.51% stake in the fir

Read more
29 May 2014 09:07

UK BROKER RATINGS: Credit Suisse Downgrades National Grid To Neutral

LONDON (Alliance News) - The following UK shares received analyst recommendations Thursday morning:
----------
FTSE 100
----------
TRADERS: CREDIT SUISSE CUTS NATIONAL GRID TO 'NEUTRAL' ('OUTPERFORM')
----------
BERENBERG RAISES LEGAL & GENER

Read more
28 May 2014 14:00

FTSE 250 movers: De La Rue climbs on profit, broker comment

Banknote printer De La Rue rose after it posted a 43% jump in full-year underlying operating profit and said it has entered the new financial year with a good order book. Helping it higher was Investec, which upped its target price from 890p to 915p and left its 'buy' recommendation unaltered. Al

Read more
28 May 2014 12:20

Hikma Pharmaceuticals to expand injectables business with acquisition

Hikma Pharmaceuticals has agreed to acquire certain key assets of the Bedford Laboratories generic injectables business from US-based Ben Venue Laboratories for up to 300m dollars. The purchase will be made for an initial $225m upfront cash payment as well as up to a further $75m in contingent cash

Read more
28 May 2014 11:38

Hikma To Purchase US Injectables Business In Deal Worth Up To USD300 Million

LONDON (Alliance News) - Hikma Pharmaceuticals PLC Wednesday said it has agreed to purchase the assets of Ben Venue Laboratories Inc's US generic injectables business for up to USD300.0 million, in a move to strengthen its position in the area. In a statement, Hikma said it will pay USD225.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.